Tengion issues updates on clinical trial following patient deaths
Tengion's clinical trial of its Neo-Urinary Conduit system will continue after 2 of the 6 enrolled patients died from causes unrelated to the trial.
Tengion  (NSDQ:TNGN ) plans to complete enrollment its in Neo-Urinary Conduit clinical trial following the deaths of 2 of the 6 enrolled patients after deeming the deaths unrelated to the device or surgical procedure.
"We are deeply saddened to hear of the passing of these 2 patients," Tengion president & CEO John Miclot said in prepared remarks. "We are grateful for their trial participation, which provided key insights into the safety and potential effectiveness of the Neo-Urinary Conduit, including its patency and functionality, a successfully redefined surgical procedure, a robust post-operative recovery, and the resilience of this product candidate to aggressive chemotherapeutic regimens."